Business
miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates
Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data; additional NIH grant funding
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data; additional NIH grant funding triggeredExploratory preclinical safety and pharmacokinetic data for MRG-229 expected before year endPlan to receive guidance from the FDA on proposed regulatory pathway for cobomarsen in ATLL before year endA majority of patients in the Phase 2 SOLAR trial of cobomarsen in CTCL have continued to receive uninterrupted treatment and are being evaluated for clinical responseReported $30.6 million in cash and cash equivalents as of June 30, 2020; anticipate cash runway into Q3 2021 BOULDER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the second quarter ended June 30, 2020 and provided business updates.\n “The miRagen team continues to execute on our strategy across multiple product opportunities, by pursuing guidance from the FDA on a development pathway for cobomarsen in ATLL, delivering preclinical data for MRG-229 in pulmonary fibrosis models that triggered NIH funding to support large animal safety and pharmacokinetic studies, and working closely with our clinical centers to ensure our ability to deliver topline data from the planned interim analysis in the Phase 2 SOLAR trial,” said William S. Marshall, Ph.D., miRagen’s President and Chief Executive Officer. “We are encouraged by the preclinical and clinical safety and efficacy data we have generated across all of our programs and energized about the potential of microRNA-based therapies to bring benefit to patients in need.” Summary of Program Highlights this Quarter Cobomarsen: Cobomarsen is currently being evaluated for the potential treatment of patients with miR-155 elevated hematological malignancies, including Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia/Lymphoma (ATLL). CTCL: As a result of the COVID-19 pandemic, the Company has seen an impact on clinical activities at some sites where the SOLAR trial is being conducted. However, with a majority of patients in the SOLAR trial continuing to receive uninterrupted treatment and evaluation for clinical response, the impact has been lim...